VP16-213 in combined modality treatment of small cell carcinoma of the lung

Steven B. Newman, Jacob D. Bitran, Harvey M. Golomb, Philip C. Hoffman, Tom R. DeMeester, Vathsala Raghavan

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Thirty-four previously untreated patients with histologically proven small cell carcinoma of the lung were treated with a combined modality therapy program that incorporated VP16-213, an epipodophyllotoxin derivative, into the chemotherapy regimen. Initial therapy for two cycles was with V-CAM, VP16-213, cyclophosphamide, doxorubicin and methotrexate. Following two cycles of V-CAM each patient received radiation therapy consisting of 4000 rads to the primary site, both hila and the mediastinum, as well as 2000 rads as prophylaxis to the whole brain. After a one-week rest period the patients received monthly cycles of V-CAM until death. Of 10 patients with stage IIIM0 disease, 7 had a complete response (CR), 1 a partial response (PR) and 2 had progressive disease. The median survival was still not reached by approximately 18 months. Of 24 patients with supraclavicular and/or metastatic disease there were only 5 patients with a CR, 11 with a PR and 8 with progressive disease. Their median survival was approximately 9 months. The 70% overall response rate and 9.3-month median survival of the entire group are essentially the same results as those in previously reported studies. There appears to be no additional benefit when VP 16-213 is incorporated into our combined modality program.

Original languageEnglish
Pages (from-to)343-346
Number of pages4
JournalEuropean Journal of Cancer and Clinical Oncology
Volume18
Issue number4
DOIs
StatePublished - Jan 1 1982
Externally publishedYes

Fingerprint

Small Cell Lung Carcinoma
Survival
Therapeutics
Podophyllotoxin
Combined Modality Therapy
Mediastinum
Etoposide
Methotrexate
Doxorubicin
Cyclophosphamide
Radiotherapy
Drug Therapy
Brain

ASJC Scopus subject areas

  • Oncology

Cite this

Newman, S. B., Bitran, J. D., Golomb, H. M., Hoffman, P. C., DeMeester, T. R., & Raghavan, V. (1982). VP16-213 in combined modality treatment of small cell carcinoma of the lung. European Journal of Cancer and Clinical Oncology, 18(4), 343-346. https://doi.org/10.1016/0277-5379(82)90004-9

VP16-213 in combined modality treatment of small cell carcinoma of the lung. / Newman, Steven B.; Bitran, Jacob D.; Golomb, Harvey M.; Hoffman, Philip C.; DeMeester, Tom R.; Raghavan, Vathsala.

In: European Journal of Cancer and Clinical Oncology, Vol. 18, No. 4, 01.01.1982, p. 343-346.

Research output: Contribution to journalArticle

Newman, SB, Bitran, JD, Golomb, HM, Hoffman, PC, DeMeester, TR & Raghavan, V 1982, 'VP16-213 in combined modality treatment of small cell carcinoma of the lung', European Journal of Cancer and Clinical Oncology, vol. 18, no. 4, pp. 343-346. https://doi.org/10.1016/0277-5379(82)90004-9
Newman, Steven B. ; Bitran, Jacob D. ; Golomb, Harvey M. ; Hoffman, Philip C. ; DeMeester, Tom R. ; Raghavan, Vathsala. / VP16-213 in combined modality treatment of small cell carcinoma of the lung. In: European Journal of Cancer and Clinical Oncology. 1982 ; Vol. 18, No. 4. pp. 343-346.
@article{221878ebf7974dc5bc39176aa05a9033,
title = "VP16-213 in combined modality treatment of small cell carcinoma of the lung",
abstract = "Thirty-four previously untreated patients with histologically proven small cell carcinoma of the lung were treated with a combined modality therapy program that incorporated VP16-213, an epipodophyllotoxin derivative, into the chemotherapy regimen. Initial therapy for two cycles was with V-CAM, VP16-213, cyclophosphamide, doxorubicin and methotrexate. Following two cycles of V-CAM each patient received radiation therapy consisting of 4000 rads to the primary site, both hila and the mediastinum, as well as 2000 rads as prophylaxis to the whole brain. After a one-week rest period the patients received monthly cycles of V-CAM until death. Of 10 patients with stage IIIM0 disease, 7 had a complete response (CR), 1 a partial response (PR) and 2 had progressive disease. The median survival was still not reached by approximately 18 months. Of 24 patients with supraclavicular and/or metastatic disease there were only 5 patients with a CR, 11 with a PR and 8 with progressive disease. Their median survival was approximately 9 months. The 70{\%} overall response rate and 9.3-month median survival of the entire group are essentially the same results as those in previously reported studies. There appears to be no additional benefit when VP 16-213 is incorporated into our combined modality program.",
author = "Newman, {Steven B.} and Bitran, {Jacob D.} and Golomb, {Harvey M.} and Hoffman, {Philip C.} and DeMeester, {Tom R.} and Vathsala Raghavan",
year = "1982",
month = "1",
day = "1",
doi = "10.1016/0277-5379(82)90004-9",
language = "English",
volume = "18",
pages = "343--346",
journal = "European Journal of Cancer and Clinical Oncology",
issn = "0277-5379",
publisher = "Pergamon Press",
number = "4",

}

TY - JOUR

T1 - VP16-213 in combined modality treatment of small cell carcinoma of the lung

AU - Newman, Steven B.

AU - Bitran, Jacob D.

AU - Golomb, Harvey M.

AU - Hoffman, Philip C.

AU - DeMeester, Tom R.

AU - Raghavan, Vathsala

PY - 1982/1/1

Y1 - 1982/1/1

N2 - Thirty-four previously untreated patients with histologically proven small cell carcinoma of the lung were treated with a combined modality therapy program that incorporated VP16-213, an epipodophyllotoxin derivative, into the chemotherapy regimen. Initial therapy for two cycles was with V-CAM, VP16-213, cyclophosphamide, doxorubicin and methotrexate. Following two cycles of V-CAM each patient received radiation therapy consisting of 4000 rads to the primary site, both hila and the mediastinum, as well as 2000 rads as prophylaxis to the whole brain. After a one-week rest period the patients received monthly cycles of V-CAM until death. Of 10 patients with stage IIIM0 disease, 7 had a complete response (CR), 1 a partial response (PR) and 2 had progressive disease. The median survival was still not reached by approximately 18 months. Of 24 patients with supraclavicular and/or metastatic disease there were only 5 patients with a CR, 11 with a PR and 8 with progressive disease. Their median survival was approximately 9 months. The 70% overall response rate and 9.3-month median survival of the entire group are essentially the same results as those in previously reported studies. There appears to be no additional benefit when VP 16-213 is incorporated into our combined modality program.

AB - Thirty-four previously untreated patients with histologically proven small cell carcinoma of the lung were treated with a combined modality therapy program that incorporated VP16-213, an epipodophyllotoxin derivative, into the chemotherapy regimen. Initial therapy for two cycles was with V-CAM, VP16-213, cyclophosphamide, doxorubicin and methotrexate. Following two cycles of V-CAM each patient received radiation therapy consisting of 4000 rads to the primary site, both hila and the mediastinum, as well as 2000 rads as prophylaxis to the whole brain. After a one-week rest period the patients received monthly cycles of V-CAM until death. Of 10 patients with stage IIIM0 disease, 7 had a complete response (CR), 1 a partial response (PR) and 2 had progressive disease. The median survival was still not reached by approximately 18 months. Of 24 patients with supraclavicular and/or metastatic disease there were only 5 patients with a CR, 11 with a PR and 8 with progressive disease. Their median survival was approximately 9 months. The 70% overall response rate and 9.3-month median survival of the entire group are essentially the same results as those in previously reported studies. There appears to be no additional benefit when VP 16-213 is incorporated into our combined modality program.

UR - http://www.scopus.com/inward/record.url?scp=0019953459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019953459&partnerID=8YFLogxK

U2 - 10.1016/0277-5379(82)90004-9

DO - 10.1016/0277-5379(82)90004-9

M3 - Article

C2 - 6288390

AN - SCOPUS:0019953459

VL - 18

SP - 343

EP - 346

JO - European Journal of Cancer and Clinical Oncology

JF - European Journal of Cancer and Clinical Oncology

SN - 0277-5379

IS - 4

ER -